
Transcend Therapeutics Gets Breakthrough Therapy Designation for TSND-201 in PTSD
Transcend Therapeutics, a clinical-stage biotech focused on neuropsychiatric treatments, announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational drug TSND-201 (methylone) for Post- …